Acasă › Limfom Burkitt › Ohio › Cincinnati
Studii clinice pentru Limfom Burkitt în Cincinnati, OH
12 studii pentru Limfom Burkitt caută participanți în și în jurul orașului Cincinnati (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
În curs de recrutareFaza 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
În curs de recrutareFaza 3
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · La 15 mi distanță
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
În curs de recrutareStudiu observațional
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
În curs de recrutareFaza 2
- University of Cincinnati Cancer Center-UC Medical Center, Cincinnati
- University of Cincinnati Cancer Center-West Chester, West Chester · La 15 mi distanță
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
În curs de recrutareFaza 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
În curs de recrutareFaza 3
- University of Cincinnati Medical Center, Cincinnati
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
În curs de recrutareFaza 3
- Cincinnati Children's Hospital Medical Center (Data Collection Only), Cincinnati
A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
În curs de recrutareFaza 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
În curs de recrutareFaza 3
- Cincinnati Children's Hospital Medical Center, Cincinnati
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
În curs de recrutareFaza 2
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of Inotuzumab Ozogamicin, Venetoclax, and Dexamethasone for Relapsed B-cell ALL
În curs de recrutareFaza 1
- Cincinnati Children's Hospital Medical Center, Cincinnati
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
În curs de recrutareFaza 1
- University of Cincinnati, Cincinnati
Studii pentru Limfom Burkitt în alte orașe
- Houston, TX21 studii
- Milwaukee, WI16 studii
- Philadelphia, PA16 studii
- New York City, NY14 studii
- Chicago, IL14 studii
- Atlanta, GA12 studii
- Seattle, WA11 studii
- Boston, MA10 studii
- Durham, NC10 studii
- Aurora, CO10 studii
- Los Angeles, CA10 studii
- Kansas City, MO10 studii
Alte studii în Cincinnati
- Cancer pulmonar cu celule non-pătrate35 studii
- Cancer (toate tipurile)27 studii
- Cancer de sân25 studii
- Insuficiență cardiacă24 studii
- Cancer colorectal21 studii
- Leucemie mieloasă acută20 studii
- Cancer metastatic20 studii
- Cancer ovarian19 studii
- Cancer pulmonar19 studii
- Obezitate19 studii
- Cancer de prostată18 studii
- Mielom multiplu17 studii
Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.